How much funding has Third Harmonic Bio raised?

Third Harmonic Bio has raised $155.0M in total funding, most recently a Series B round.

Who are Third Harmonic Bio's investors?

Third Harmonic Bio's investors include Atlas Venture, OrbiMed, BVF Partners.

When was Third Harmonic Bio founded?

Third Harmonic Bio was founded in 2019.

Where is Third Harmonic Bio headquartered?

Third Harmonic Bio is headquartered in Boston, United States.

What industry is Third Harmonic Bio in?

Third Harmonic Bio operates in Life Sciences.

Third Harmonic Bio

IPO

Boston, United States · Founded 2019 · $155.0M raised

Life Sciences

Headquarters: Boston
Founded: 2019
Website: thirdharmonicbio.com

Total Funding: $155.0M
Last Round: $105.0M Series BDec 2021
Rounds: 3

About

Third Harmonic Bio is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, founded in 2019 by Atlas Venture. It is developing a first-in-class, highly selective oral KIT inhibitor licensed from Novartis for chronic urticaria, asthma, and other mast cell-driven allergic and inflammatory diseases. The company emerged from stealth in February 2022 with a $155 million Series B financing backed by General Atlantic and Atlas Venture. In April 2025 it announced a wind-down of operations after discontinuing its lead clinical program.

Summary

Third Harmonic Bio is a Life Sciences company based in Boston, United States, founded in 2019. It has raised $155.0M in total across 3 rounds, most recently a $105.0M Series B round in Dec 2021. Investors include Atlas Venture, OrbiMed and BVF Partners.